Early trial tests new vaccine to train immune system against tough breast cancer
NCT ID NCT03362060
Summary
This early-stage study is testing the safety of a new cancer vaccine called PVX-410, given alone and with an immunotherapy drug (pembrolizumab), in 20 patients with advanced triple-negative breast cancer. The goal is to see if the combination can safely help the patient's own immune system recognize and fight the cancer. Researchers will measure immune system activity and track side effects and cancer progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.